The long term goal of the present proposal is to develop a nanoparticle that can be targeted to tissues with specific molecular signatures. Inclusion of a contrast agent (Iron Oxide for MRI) within the nanoparticle would therefore facilitate non-invasive imaging of specific biochemical properties within tissues in-vivo. The present proposal is focused on investigating if a nanoparticle based contrast agent can be efficiently targeted to cells with specific molecular characteristics. Two well-characterized molecular targets will be investigated. The first involves targeting to endothelial cells that express alpha-V-beta-3 and alpha-V-beta-5 integrins using the sequence CDCRGDCFC. Expression of these integrins is a hallmark of endothelial cells within angiogenic vasculature (e.g. within tumors). Similarly, we will target tissues (endothelial cells and tumors) that are undergoing tissue remodeling. Since expression of the metalloproteases MMP-2 and MMP-9 is characteristic of cells that need to migrate through the extracellular matrix or basement membrane, inclusion of the CTTHWGFTLC within a nanoparticle will target nanoparticles to tumors and tumor vasculature that typically express these proteases. It is anticipated that the results from the proposed studies will provide the foundation for future development of these novel nano-structure-based strategies for non-invasive in vivo imaging of specific biochemical events.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA091724-01A1
Application #
6550007
Study Section
Special Emphasis Panel (ZRG1-SSS-7 (10))
Program Officer
Farahani, Keyvan
Project Start
2002-08-12
Project End
2003-07-31
Budget Start
2002-08-12
Budget End
2003-07-31
Support Year
1
Fiscal Year
2002
Total Cost
$183,548
Indirect Cost
Name
Molecular Therapeutics, Inc.
Department
Type
DUNS #
843026449
City
Ann Arbor
State
MI
Country
United States
Zip Code
48108